Tablets 1 Tablet
Contains active ingredients including Mebendazole .
Medical aid prices may differ from the cash price displayed.
Any questions? Visit our OTC FAQ page for more information.
Infections 1and2 Stomach And Colon Health Vermox Tablet 1
Scheduling status:Schedule 1.Proprietary name (and dosage form):Vermox® 500 mg tablet.Composition:Each tablet contains 500 mg of the active substance, mebendazole polymorph C.Pharmacological classification:A.12 Anthelmintics, Bilharzia Medicines, Filaricides, Etc.Pharmacological action:Mebendazole is a broad-spectrum anthelmintic.Mebendazole acts locally in the lumen of the gut by interfering with cellular tubulin formation in the intestines of worms. Mebendazole binds specifically to tubulin and causes ultrastructural degenerative changes in the intestine. As a result, the glucose uptake and the digestive functions of the worm are disrupted to such as extent that an autolytic process occurs.Indications:Vermox® is indicated for the treatment of single and mixed helminth gastrointestinal infestations caused by:Nematodes such as:Trichuris trichiura - (whipworm).Ancylostoma duodenale - (hookworm).Necator americanus - (hookworm).Ascaris lumbricoides - (large roundwornn).Enterobius vermicularis - (pinworm).Clinical trial data:The safety of Vermox® was evaluated in 6276 subjects who participated in 39 clinical trials for the treatment of single or mixed parasitic infestations of the gastrointestinal tract. In these 39 clinical trials, no adverse drug reactions (ADRs) occurred in > 1% of Vermox® -treated subjects. ADRs occurring in < 1 % of Vermox® treated subjects are shown in table 1. Table 1. adverse drug reactions reported by < 1% of Vermox® treated subjects in 39 clinical trials.System/organ class:Adverse reaction.Gastrointestinal disorders:Abdominal discomfort, diarrhoea, flatulence.Skin and subcutaneous tissue disorders:Rash.Postmarketing experience:Adverse drug reactions first identified during post-marketing experience with Vermox® (mebendazole) are included below:System/organ class:Adverse reaction.Blood and lymphatic system disorders:Neutropenia.Immune system disorders:Hypersensitivity including anaphylactic reaction and anaphylactoid reaction.Nervous system disorders:Convulsions.Gastrointestinal disorders:Abdominal pain.Hepatobiliary disorders:Hepatitis, abnormal liver function tests.Skin and subcutaneous tissue disorders:Toxic epidermal necrolysis, stevens Johnson syndrome, exanthema, angicedema, urticaria, alopecia.Identification:A white to faintly cream-coloured, bevel-edged tablet with-inscription on the one side and "Janssen" on the other side.Presentation:Carton containing one or more blister packs of 1 tablet.Date of publication of this package insert:25 November 2011.Customer contact centre: 0860410032 (South Africa only).Mebendazole (polymorph C) 500mg tablet.
Quantity in pack: